# Walnut Lipid Profile Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/walnut-lipid-profile-randomized-trial-evidence-review
Category: evidence-review
Summary: Walnut Lipid Profile Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are s
Last reviewed: 2026-08-06
Reviewed by: Migaku Evidence Review
# Walnut Lipid Profile Randomized Trial: What the Evidence Says

## Quick Answer

Walnut Lipid Profile Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effects of Walnut Consumption on Blood Lipid Profile and Apolipoproteins in Adults: A GRADE ‐Assessed Systematic Review and Dose–Response Meta‐Analysis of 49 Randomized Controlled Trials | systematic review | 1 | 2026-02-10 | 10.1002/fsn3.71526 |

## What The Sources Report

- One of its principal risk factors is dyslipidemia, a metabolic disorder defined by elevated plasma levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo-B), alongside reduced concentrations of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (Apo-A1) (Arvanitis and Lowenstein ). [Mashayekhi Ghazal (2026); evidence level 1]
- Likewise, Hwang et al.  found that 16 weeks of walnut supplementation increased HDL-C levels but did not affect other lipid markers in individuals with metabolic syndrome. [Mashayekhi Ghazal (2026); evidence level 1]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For walnut lipid profile randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Mashayekhi Ghazal (2026). Effects of Walnut Consumption on Blood Lipid Profile and Apolipoproteins in Adults: A GRADE ‐Assessed Systematic Review and Dose–Response Meta‐Analysis of 49 Randomized Controlled Trials. DOI: 10.1002/fsn3.71526. PMCID: PMC12887447. PMID: 41676011. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12887447/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.